ARDELYX, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
ARDELYX, INC. (ARDX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $3.19 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-02-19
- ARDELYX, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2021-03-31 was $6.51, a 23.53% increase year-over-year.
- ARDELYX, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2020-09-30 was $4.09.
- ARDELYX, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2020-06-30 was $5.14.
- ARDELYX, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2020-03-31 was $5.27.
- ARDELYX, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $3.19, a 48.71% decline from fiscal 2024.
- ARDELYX, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $6.22, a 163.56% increase from fiscal 2023.
- ARDELYX, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $2.36, a 274.60% increase from fiscal 2022.
- ARDELYX, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $0.63, a 83.93% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|---|---|---|
| 2025-12-31 | $3.19 10-K · filed 2026-02-19 | |||
| 2024-12-31 | $6.22 10-K · filed 2026-02-19 | |||
| 2023-12-31 | $2.36 10-K · filed 2026-02-19 | |||
| 2022-12-31 | $0.63 10-K · filed 2025-02-20 | |||
| 2021-12-31 | $3.92 10-K · filed 2024-02-22 | |||
| 2021-03-31 | $6.51 10-Q · filed 2021-05-06 | |||
| 2020-12-31 | $4.82 10-K · filed 2023-03-02 | |||
| 2020-09-30 | $4.09 10-Q · filed 2020-11-05 | $5.03 10-Q · filed 2020-11-05 | ||
| 2020-06-30 | $5.14 10-Q · filed 2020-08-06 | $5.19 10-Q · filed 2020-08-06 | ||
| 2020-03-31 | $5.27 10-Q · filed 2020-05-07 | |||
| 2019-12-31 | $1.79 10-K · filed 2022-02-28 | |||
| 2018-12-31 | $4.29 10-K · filed 2021-03-08 | |||
| 2017-12-31 | $8.19 10-K · filed 2020-03-06 | |||
| 2016-12-31 | $7.69 10-K · filed 2019-03-06 | |||
| 2015-12-31 | $12.91 10-K · filed 2018-03-14 | |||
| 2014-12-31 | $18.53 10-K · filed 2017-02-17 | |||
| 2014-09-30 | $10.96 10-Q · filed 2014-11-07 | |||
| 2014-06-30 | $10.98 10-Q · filed 2014-08-08 | $10.96 10-Q · filed 2014-08-08 | ||
| 2013-12-31 | $2.68 10-K · filed 2016-03-04 | |||
| 2013-09-30 | $2.70 10-Q · filed 2014-11-07 | $2.68 10-Q · filed 2014-11-07 | ||
| 2013-06-30 | $0.00 10-Q · filed 2014-08-08 | $2.65 10-Q · filed 2014-08-08 | ||
| 2012-12-31 | $2.56 10-K · filed 2015-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |